RadMD is a full service, global imaging core lab for Phase 1-Phase 3.  Our oncology focus means expert, responsive teams who move quickly and are adaptable to your program.   Our industry leading reader group, managed by  medical & scientific affairs team continues to set higher standards for quality and innovation to meet demands of clinical development today. For more information, visit https://radmdimaging.com/

Annexin Pharmaceuticals is a publicly listed (NASDAQ/First North, Sweden) clinical stage biotech company advancing ANXV (a human recombinant protein Annexin A5 ) first-in-class biologic with a broad therapeutic potential. The company focus is in ophthalmology and oncology incl ADC. Retinal Vein Occlusion is the primary indication in focus. Here ANXV has a potential to become a first in line first in class treatment. The mode of action is non-overlapping to the current standard of care anti-VEGF. The Phase 2 clinical trial in Retinal Vein Occlusion is approved by the FDA and is currently enrolling in the USA. In immunooncology, the company is advancing ANXV as a monotherapy and as a carrier for chemo (Protein Drug Conjugate). The CMC process is optimized and is being prepared for commercial upscaling. The IP portfolio is strong with the key patents recently issued in major territories. Annexin Pharmaceuticals management are open to looking at the full range of strategic options that would facilitate long term development.

Immunai's engineering-first platform maps the immune system for the discovery and augmentation of novel therapeutics, through single-cell sequencing, functional genomics, big data and ML. Immunai holds a successful track record of partnering with leading pharmaceutical and biotech companies, academic institutions and hospitals to optimize their preclinical and clinical decision-making. To learn more, please visit https://www.immunai.com/

Suttons Creek is pharma’s device team. Any life sciences company going to market with a drug delivery system needs a device team experienced in combination products working alongside their drug team. That device team includes specialists in areas like quality, regulatory, vendor selection and management, systems engineering, risk management, clinical development, human factors, and commercialization. Suttons Creek has over 650 years of combined experience and 120+ combination product projects under its belt. Our talent pool of subject matter experts specializes in all device-related aspects of the combination product lifecycle, from strategic planning through development to launch and postmarket activities. Our history of success proves that hiring our experienced device team results in faster time to market, reduced risk, improved patient experience and adherece, and lower overall cost (higher profit). For more information, visit https://suttonscreek.com/

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

HistoWiz accelerates scientific research and discoveries by automating histology and digital pathology solutions. The company is a leading provider of end-to-end solutions for digital pathology, offering comprehensive services from slide creation to digitization, image analysis, and pathology consultations. Its platform, PathologyMapTM, empowers researchers with tools for efficient image management and analysis. Through automation and AI, HistoWiz’s innovations promote a deeper understanding of biology by enabling global collaboration to drive scientific advancement. HistoWiz was founded in 2013 and is headquartered in Long Island City, New York. 

Radiant Biotherapeutics is a revolutionary antibody platform company leading the next frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant’s proprietary Multabody™ platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies have potential to deliver a new class of biologics to tackle complex, heterogenous diseases, such as cancer, that often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The ground-breaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform’s broad scientific and clinical utility. For more, visit radiantbio.com.

Putnam, an Inizio Advisory company, is a leading scientific and strategic consulting partner that helps the global life science community make confident decisions, build value, and bring life-changing innovations to clinicians and patients. For more than 30 years, our rigorous, bespoke approach and globally diverse team have delivered unrivaled depth across therapeutic areas, business functions, geographic markets, healthcare sectors, and technology platforms to maximize the human impact and commercial success of client innovations. To learn more, please visit https://www.putassoc.com/ 

PPD, part of Thermo Fisher Scientific, provides clinical development and analytical services that enhance customer innovation and productivity. Utilizing patient-centered strategies and data analytics, we cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites and comprehensive laboratory service. To learn more, please visit https://www.ppd.com/

TREND Community turns the conversations of people who have rare, chronic, and emerging diseases and their caregivers/care partners into actionable insights through our proprietary evidence-accelerator approach. Above all, we prioritize the privacy and trust of every community member. For more information visit https://trend.community.

Innovative Trials is a prominent international company specializing in patient recruitment and retention for clinical trials. Boasting 14 years of experience, Innovative Trials provides three fundamental services in this domain: Site Enrollment Optimization, facilitated by ‘boots-on-the-ground’ local patient recruitment expert operating in more than 70 countries, Materials & Digital Advertising services, and Navigator, a 1:1 support service for patients, caregivers and sites. With expertise in over 300 trials, spanning 25 therapeutic areas and encompassing over 90 conditions, Innovative Trials has established itself as a trusted and seasoned partner for pharmaceutical companies, contract research organizations (CROs) and biotechnology companies. To learn more, please visit https://innovativetrials.com/